Difference between revisions of "Profiles"

From QIBA Wiki
Jump to: navigation, search
(Stage 1: Public Comment Profiles)
(Stage 1: Public Comment Profiles)
Line 43: Line 43:
 
*[[Media:QIBA_Profile_MSK-Cartilage-Stage1_Profile.pdf|MSK Profile: MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease]] (<font color=##00cc00>'''Open for comment: June 26, 2020 - September 29, 2020<font>)
 
*[[Media:QIBA_Profile_MSK-Cartilage-Stage1_Profile.pdf|MSK Profile: MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease]] (<font color=##00cc00>'''Open for comment: June 26, 2020 - September 29, 2020<font>)
  
*[[Media:QIBA_DSC-MRI_Stage1_Profile.pdf|Dynamic Susceptibility Contrast MRI (DSC-MRI) Profile 2020-01-29]] (<font color=#8b0000>'''closed''' on May 15, 2020<font>)
+
*[[Media:QIBA_DSC-MRI_Stage1_Profile.pdf|MR Dynamic Susceptibility Contrast (DSC-MRI) 2020-01-29]] (<font color=#8b0000>'''closed''' on May 15, 2020<font>)
  
*[[Media:QIBA_US_SWS_Profile_10.21.19.pdf|QIBA US Measurement of Shear Wave Speed for Estimation of Liver Fibrosis Profile 2019-10-21]] ('''closed''' on December 18, 2019)
+
*[[Media:QIBA_US_SWS_Profile_10.21.19.pdf|US Shear Wave Speed for Liver Fibrosis 2019-10-21]] ('''closed''' on December 18, 2019)
  
:*[[Media:SWS Checklists-Appendix E.xlsx|Appendix E: QIBA US SWS Checklists for Implementation of the SWS Profile, 2019-10-21]] ('''closed''' on December 18, 2019)
+
:*[[Media:SWS Checklists-Appendix E.xlsx|Appendix E: SWS Checklists, 2019-10-21]] ('''closed''' on December 18, 2019)
  
*[[Media:QIBA_CT_Lung_Density_Profile_090319-clean.pdf | QIBA CT Lung Density Profile 2019-09-03]] (Contains Conformance Checklist, Appendix B) ('''closed''' on October 16, 2019)
+
*[[Media:QIBA_CT_Lung_Density_Profile_090319-clean.pdf | CT Lung Density 2019-09-03]] (Contains Conformance Checklist, Appendix B) ('''closed''' on October 16, 2019)
  
:*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|QIBA CT Lung Density Protocols-Appendix E, 2019-06-26]] ('''closed''' on October 16, 2019)
+
:*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]] ('''closed''' on October 16, 2019)
  
*[[Media:QIBA_fMRI_Profile_1_PC-rev1.pdf| QIBA fMRI Profile 2017-06-19]] (''Closed on December 31, 2017'')
+
*[[Media:QIBA_fMRI_Profile_1_PC-rev1.pdf| fMRI for Sensorimotor Mapping 2017-06-19]] (''Closed on December 31, 2017'')
  
  

Revision as of 23:00, 1 July 2020

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Technically Confirmed Profiles

  • Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
  • Assessment Procedures (refer to Section 4 in the Profile document - pg 30)


Stage 2: Consensus Profiles

Stage 1: Public Comment Profiles

Please submit comments using the online form


Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.

Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. QIBA, Date. Available from: URL

Example:

QIBA SPECT Biomarker Committee. Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases, Quantitative Imaging Biomarkers Alliance. Version 1.1. Profile Stage: Consensus. QIBA, June 30, 2017. Available from: http://qibawiki.rsna.org/index.php/Profiles


Statements of Endorsement


See Also